Logo image of LXRX

LEXICON PHARMACEUTICALS INC (LXRX) Stock Fundamental Analysis

NASDAQ:LXRX - Nasdaq - US5288723027 - Common Stock - Currency: USD

0.29  -0.41 (-58.54%)

After market: 0.3284 +0.04 (+13.24%)

Fundamental Rating

2

Taking everything into account, LXRX scores 2 out of 10 in our fundamental rating. LXRX was compared to 571 industry peers in the Biotechnology industry. LXRX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, LXRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LXRX has reported negative net income.
LXRX had a negative operating cash flow in the past year.
LXRX had negative earnings in 4 of the past 5 years.
In the past 5 years LXRX reported 4 times negative operating cash flow.
LXRX Yearly Net Income VS EBIT VS OCF VS FCFLXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M

1.2 Ratios

With a Return On Assets value of -67.39%, LXRX is not doing good in the industry: 64.46% of the companies in the same industry are doing better.
With a Return On Equity value of -121.22%, LXRX is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -67.39%
ROE -121.22%
ROIC N/A
ROA(3y)-64.59%
ROA(5y)-38.28%
ROE(3y)-118.18%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
LXRX Yearly ROA, ROE, ROICLXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 400

1.3 Margins

LXRX has a Gross Margin of 93.54%. This is amongst the best in the industry. LXRX outperforms 94.64% of its industry peers.
In the last couple of years the Gross Margin of LXRX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for LXRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.65%
LXRX Yearly Profit, Operating, Gross MarginsLXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LXRX has more shares outstanding
Compared to 5 years ago, LXRX has more shares outstanding
Compared to 1 year ago, LXRX has a worse debt to assets ratio.
LXRX Yearly Shares OutstandingLXRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
LXRX Yearly Total Debt VS Total AssetsLXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -8.65, we must say that LXRX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of LXRX (-8.65) is worse than 70.71% of its industry peers.
LXRX has a Debt/Equity ratio of 0.56. This is a neutral value indicating LXRX is somewhat dependend on debt financing.
The Debt to Equity ratio of LXRX (0.56) is worse than 76.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z -8.65
ROIC/WACCN/A
WACC11.55%
LXRX Yearly LT Debt VS Equity VS FCFLXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 7.45 indicates that LXRX has no problem at all paying its short term obligations.
LXRX has a Current ratio of 7.45. This is in the better half of the industry: LXRX outperforms 70.71% of its industry peers.
LXRX has a Quick Ratio of 7.43. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX's Quick ratio of 7.43 is fine compared to the rest of the industry. LXRX outperforms 70.89% of its industry peers.
Industry RankSector Rank
Current Ratio 7.45
Quick Ratio 7.43
LXRX Yearly Current Assets VS Current LiabilitesLXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

LXRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.32%.
The Revenue has grown by 945.80% in the past year. This is a very strong growth!
Measured over the past years, LXRX shows a very negative growth in Revenue. The Revenue has been decreasing by -54.71% on average per year.
EPS 1Y (TTM)1.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)945.8%
Revenue growth 3Y-63.12%
Revenue growth 5Y-54.71%
Sales Q2Q%980.25%

3.2 Future

Based on estimates for the next years, LXRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.95% on average per year.
LXRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 155.21% yearly.
EPS Next Y12.15%
EPS Next 2Y18.38%
EPS Next 3Y13.73%
EPS Next 5Y15.95%
Revenue Next Year538.53%
Revenue Next 2Y176.53%
Revenue Next 3Y149.03%
Revenue Next 5Y155.21%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LXRX Yearly Revenue VS EstimatesLXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
LXRX Yearly EPS VS EstimatesLXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXRX Price Earnings VS Forward Price EarningsLXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXRX Per share dataLXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as LXRX's earnings are expected to grow with 13.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.38%
EPS Next 3Y13.73%

More info and screens

0

5. Dividend

5.1 Amount

LXRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (3/3/2025, 8:00:00 PM)

After market: 0.3284 +0.04 (+13.24%)

0.29

-0.41 (-58.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-12 2025-03-12/amc
Inst Owners84.5%
Inst Owner Change3.34%
Ins Owners0.74%
Ins Owner Change0%
Market Cap104.83M
Analysts81.67
Price Target3.67 (1165.52%)
Short Float %12.43%
Short Ratio8.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.19%
Min EPS beat(2)-7.28%
Max EPS beat(2)11.66%
EPS beat(4)3
Avg EPS beat(4)3.71%
Min EPS beat(4)-7.28%
Max EPS beat(4)11.66%
EPS beat(8)5
Avg EPS beat(8)-1.81%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)13
Avg EPS beat(16)8.24%
Revenue beat(2)0
Avg Revenue beat(2)-42.19%
Min Revenue beat(2)-42.95%
Max Revenue beat(2)-41.43%
Revenue beat(4)0
Avg Revenue beat(4)-37.48%
Min Revenue beat(4)-44.59%
Max Revenue beat(4)-20.92%
Revenue beat(8)1
Avg Revenue beat(8)-0.68%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-29.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.41%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.05
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.01
BVpS0.49
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.39%
ROE -121.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.54%
FCFM N/A
ROA(3y)-64.59%
ROA(5y)-38.28%
ROE(3y)-118.18%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.61%
Cap/Sales 10.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.45
Quick Ratio 7.43
Altman-Z -8.65
F-Score5
WACC11.55%
ROIC/WACCN/A
Cap/Depr(3y)269.95%
Cap/Depr(5y)163.2%
Cap/Sales(3y)579.68%
Cap/Sales(5y)347.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y12.15%
EPS Next 2Y18.38%
EPS Next 3Y13.73%
EPS Next 5Y15.95%
Revenue 1Y (TTM)945.8%
Revenue growth 3Y-63.12%
Revenue growth 5Y-54.71%
Sales Q2Q%980.25%
Revenue Next Year538.53%
Revenue Next 2Y176.53%
Revenue Next 3Y149.03%
Revenue Next 5Y155.21%
EBIT growth 1Y-36.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.86%
EBIT Next 3Y3.95%
EBIT Next 5YN/A
FCF growth 1Y-131.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-130.73%
OCF growth 3YN/A
OCF growth 5YN/A